Japan’s recent Upper House election delivered a stinging defeat for the ruling Liberal Democratic Party (LDP) and junior coalition partner…
ORGANIZATION
Stop Requiring Japanese PI Data for Global Products: JPMA Officials
If Japan is to reverse the current trend of drug lags and losses, regulatory authorities should boost development incentives and overseas communications and stop seeking PI Japanese patient data for global products, the Japan Pharmaceutical Manufacturers Association (JPMA) says. The…
To read the full story
ORGANIZATION
- Japan Needs New Pricing Scheme for Regenerative Medicine: Industry Group
July 31, 2025
- Japan Society Poised to Set Out Criteria to Standardize Regional Formularies, Eyes August Release
July 31, 2025
- Takeda Alumni Link with Osaka Biz Lobby to Support Drug Discovery
July 28, 2025
- JPMA Urges Safeguards for Patient Access in Any Future Drug Tariff Talks
July 24, 2025
- JPMA Selected for Japan Program to Cut Carbon Emissions
July 23, 2025
A recent conversation with a US biopharma senior director highlighted a critical talent gap: a strong demand for individuals with strategic management, critical thinking, and advanced business acumen-skills beyond traditional operational excellence. After the conversation, I rushed home and picked…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…